



Auxellence Arranging \$1.05 Million Secured Convertible Credit Facility

VANCOUVER, BC, Tuesday, February 23, 2016 – Auxellence Health Corporation (CSE:AID, OTCQB: AXHLF), (“Auxellence” or the “Company”) announces the arranging by the Company's Chairman of a one-year, \$1.05 million credit facility. The gross amount, including interest, shall be convertible debt, secured by the Company's Intellectual Property, under the same terms as the Private Placement announced on February, 22, 2016.

The Private Placement remains open. Expressions of interest in this financing are welcome until March 7th, 2016.

“We are very pleased with the results of the Pioneer Commercial Pilot Program of our medical device. We are now ready to speed up the execution of our roll-out plan for Canada and the European Union and advance our mission in the United States in view of the rapid increase in demand for health self-care services”, said Sydney Au, Chairman and CEO.

Contact:

Ron Ozols

Director, Auxellence Health Corporation

Email: info@auxellence.com or

ceo@auxellence.com

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://www.cnsx.ca/CNSX/Securities/Technology/Auxellence-Health-Corporation.aspx>

About Tulip™

TULIP™ is a medical device cleared for sales in Canada and Europe as a blood pressure monitor with interactive protocols. The device enables physiologically interactive health apps useful in testing, tracking, and treating common health conditions. The online system is aimed primarily at “practicing patients” interested in normalizing blood pressure, blood glucose, and body weight. Session schedules, measurement procedures, and conditioning protocols are prescribed automatically by the system from extemporaneous data acquired from the user.

About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management. The initial focus is on weight management and skin conditions.



Disclaimer for Forward-Looking Information

Statements in this press release regarding the Company which are not historical facts are “forward-looking statements” that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. The Company does not intend to update any changes to such statements, except as required by law. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbour.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES